Business Wire

18th Manufacturing World Osaka Ended with the Greatest Success!

Del

Reed Exhibitions Japan Ltd., the largest show organiser in Japan, announced that 18th Manufacturing World Osaka held from October 7 - 9, 2015 at INTEX Osaka, the Western Japan’s largest trade show for the manufacturing industry, ended with the greatest success with 1,063 exhibitors and 42,216 visitors from around the world.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151014006783/en/

Reed Exhibitions Japan announces 18th Manufacturing World Osaka ended up with 1,063 exhibitors 42,21 ...

Reed Exhibitions Japan announces 18th Manufacturing World Osaka ended up with 1,063 exhibitors 42,216 attendees, 14% up comparing to 2014 (Photo: Business Wire)

“18th Manufacturing World Osaka has been a very successful edition with absolutely exciting atmosphere by active business meetings seen everywhere in the venue,” said Takeshi Fujiwara, the show director at Reed Exhibitions. “On behalf of Show Management, I would like to thank all the exhibitors, visitors, conference speakers and the press… and everyone who was part of it. It was a great happiness for us to record the highest figures in the number of exhibitors and visitors in its 18 years history and we will endure our efforts in providing a firm base for business and to keep attracting important professionals from all over the world.”

The number of visitors represents the sum of those visited 18th Manufacturing World Osaka and 3rd Highly-functional Material World Osaka.

Highlights

  • 14% increasing in exhibitors: 1,063 exhibitors (2015), comparing to 932 exhibitors (2014)

Though the number of exhibitors in 2014 was the largest in its 17-year history, 2015 show recorded the largest number of exhibitors once again increased to 1,063 exhibitors.

  • Most-ever 181 international exhibitors brought in latest international trend

Largest-ever 181 exhibitors from 11 countries/regions outside Japan – China, Germany, Hong Kong, India, Indonesia, Korea, Singapore, Taiwan, Thailand, United States and Vietnam – tapped the Japanese market.

China, Korea, Taiwan and Thailand held their own national pavilions, which made meeting spots where Asia’s most advanced technologies would create the latest international trend.

The growing globalization and the Japanese economy’s recovery lead to lively exchanges between overseas exhibitors and Japanese visitors. This trend is estimated to continue in 2016.

2016 Manufacturing World series

2016 schedule of Manufacturing World series is fixed and the next edition is coming back in April 2016 at Nagoya where is another center of Japanese manufacturing industry. “1st Manufacturing World Nagoya”, a long-awaited trade show among Japanese manufacturing industry is eventually launched in April 2016.

For exhibitors: According to the big satisfaction of exhibitors and the fact that most exhibitors have already booked their exhibit space in 2016, remaining exhibit spaces has been already very limited. If you are interested in being exhibitor, contact Show Management to secure your booth now.

2016 Show Schedule

Nagoya Edition
Dates: April 19 – 21, 2016
Venue:Portmesse Nagoya, Japan
http://www.japan-mfg.jp/en/nagoya/

Tokyo Edition
Dates: June 22 – 24, 2016
Venue: Tokyo Big Sight, Japan
http://www.japan-mfg.jp/en/

Osaka Edition
Dates: October 5 – 7, 2016
Venue: INTEX Osaka, Japan
http://www.japan-mfg.jp/en/osaka/

Contact information

Reed Exhibitions Japan Ltd.
Kenichi Matsumoto (Mr.), Yifan Wang (Ms.), +81-3-3349-8519
Manufacturing World Show Management
matsumotok001@japan-mfg.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom